170 related articles for article (PubMed ID: 28380099)
1. The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity.
Sukgen EA; Koçluk Y
Arq Bras Oftalmol; 2017; 80(1):30-34. PubMed ID: 28380099
[TBL] [Abstract][Full Text] [Related]
2. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
Harper CA; Wright LM; Young RC; Read SP; Chang EY
Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography.
Wu L; Li M; Wang L; Yan H; Zhou Z; Fan J; Zhou Y; Gou K; Guo C; Wang Y; Zhang Z
Sci Rep; 2023 Nov; 13(1):19946. PubMed ID: 37968276
[TBL] [Abstract][Full Text] [Related]
4. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
Sahinoglu-Keskek N; Akkoyun I; Torer B
Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
[TBL] [Abstract][Full Text] [Related]
5. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C
Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity.
Aldebasi T; Guma MA; Bashir R; Al Saif S; Altwaijri WA; Al Bekairy AM
Med Princ Pract; 2019; 28(6):526-532. PubMed ID: 30995663
[TBL] [Abstract][Full Text] [Related]
7. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity].
Tian R; Zhang G; Tang S; Guo J; Tan W
Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583
[TBL] [Abstract][Full Text] [Related]
8. Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.
Sukgen EA; Koçluk Y
Cutan Ocul Toxicol; 2017 Dec; 36(4):356-361. PubMed ID: 28277877
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
[TBL] [Abstract][Full Text] [Related]
10. Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study.
Chen Y; Wang S; Chen S; Chen X; Han L; Zhong Q; Zhang K
BMC Ophthalmol; 2022 Jun; 22(1):271. PubMed ID: 35729540
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
Ekinci DY; Çelik K
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
[TBL] [Abstract][Full Text] [Related]
13. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.
Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H
Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964
[TBL] [Abstract][Full Text] [Related]
14. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
Chandra P; Kumawat D; Agarwal D; Chawla R
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.
Bassiouny RM; Gaafar WM; El Nokrashy A; Abdelhameed AG; Attallah EA; Elgharieb AG; Bassiouny MR
Eye (Lond); 2022 Nov; 36(11):2137-2143. PubMed ID: 34711941
[TBL] [Abstract][Full Text] [Related]
16. Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis.
Xia F; Lyu J; Peng J; Zhao P
Graefes Arch Clin Exp Ophthalmol; 2022 Sep; 260(9):2837-2846. PubMed ID: 35438363
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.
Cheng Y; Zhu X; Linghu D; Liang J
Acta Ophthalmol; 2020 Dec; 98(8):e1004-e1008. PubMed ID: 32385940
[TBL] [Abstract][Full Text] [Related]
18. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
Mintz-Hittner HA; Geloneck MM; Chuang AZ
Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619
[TBL] [Abstract][Full Text] [Related]
19. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
Tong Q; Yin H; Zhao M; Li X; Yu W
BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
